EXTON, Pa., April 29, 2021 /PRNewswire/ -- West
Pharmaceutical Services, Inc. (NYSE: WST) today announced its
financial results for the first-quarter 2021 and updated full-year
2021 financial guidance.
First-Quarter 2021 Summary (comparisons to prior-year
period)
- Net sales of $670.7 million grew
36.5%; organic sales growth was 31.1%.
- Reported-diluted EPS of $1.99
increased 101%.
- Adjusted-diluted EPS of $2.05
increased 103%.
- The Company is raising full-year 2021 net sales guidance to a
new range of $2.630 billion to
$2.655 billion, compared to a prior
range of $2.500 billion to
$2.525 billion. The Company is
raising full-year 2021 adjusted-diluted EPS guidance to a new range
of $6.95 to $7.10, compared to a prior range of $6.00 to $6.15.
"Adjusted-diluted EPS" and "organic sales growth" are Non-U.S.
GAAP measurements. See discussion under the heading "Non-U.S.
GAAP Financial Measures" in this release.
"We delivered another solid performance in the first quarter
with strong organic sales growth from both our base business as
well as increased demand for our products associated with COVID-19
vaccines," said Eric M. Green,
President and Chief Executive Officer. "I am proud of the
relentless focus and consistent execution of our global team
members to deliver critical components and solutions during these
times. With a strong start to the year, we are raising our
full-year financial guidance. West will continue to play an
integral role with our customers as they develop and bring new
medicines to the market for a brighter future."
Proprietary Products Segment
Net sales grew by 45.6%
to $543.7 million. Organic
sales growth was 39.6% with currency translation increasing sales
growth by 600 basis points. High-value products (components
and devices) represented more than 70% of segment sales and
generated double-digit organic sales growth, led by customer demand
for FluroTec®, Westar®, Daikyo®
and NovaPure® components as well as for devices such as
Daikyo Crystal Zenith® syringes and cartridges.
All three market units had double-digit organic sales growth,
led by strong performance in the Biologics market unit.
Contract-Manufactured Products Segment
Net sales grew
by 7.6% to $127.1 million.
Organic sales growth was 4.0% with currency translation increasing
sales growth by 360 basis points. Segment performance was led
by sales of components for drug-injection delivery devices as well
as diagnostic devices.
Financial Highlights
Operating cash flow was
$88.7 million, an increase of
55.3%. Capital expenditures in the quarter were $54.7 million. Free cash flow (operating
cash flow minus capital expenditures) was $34.0 million, an increase of 36%.
During the quarter, the Company repurchased 479,000 shares for
$137.1 million at an average share
price of $286.23 under its share
repurchase program.
Our capital and financial resources, including overall
liquidity, remain strong. We believe that cash on hand and
cash generated from operations, together with availability under
our Credit Facility, will be adequate to address our foreseeable
liquidity needs based on our current expectations of our business
operations, capital expenditures and scheduled payments of debt
obligations.
Full-Year 2021 Financial Guidance
- Full-year 2021 net sales are expected to be in a range of
$2.630 billion to $2.655 billion, compared to a prior guidance
range of $2.500 billion to
$2.525 billion.
-
- Organic sales growth is expected to be in a range of 19% to
20%, compared to a prior range of 13% to 14%.
- Net sales guidance includes an estimated full-year 2021 benefit
of $75 million based on current
foreign exchange rates.
- Full-year 2021 adjusted-diluted EPS is expected to be in a
range of $6.95 to $7.10, compared to a prior range of $6.00 to $6.15.
-
- Full-year adjusted-diluted EPS guidance range includes an
estimated benefit of approximately $0.23 based on current foreign currency exchange
rates.
- The revised guidance includes a $0.15 EPS positive impact from first-quarter tax
benefits from stock-based compensation.
- For the remainder of the year, our EPS guidance range assumes a
tax rate of 23% and does not include potential tax benefits from
stock-based compensation. Any tax benefits associated with
stock-based compensation beyond those recorded in the first-quarter
2021 would provide a positive adjustment to our full-year EPS
guidance.
First-Quarter 2021 Conference Call
The Company will
host a conference call to discuss the results and business
expectations at 9:00 a.m. Eastern
Time today. To participate on the call please dial
877-930-8295 (U.S.) or 253-336-8738 (International). The conference
ID is 4285757.
A live broadcast of the conference call will be available at the
Company's website, www.westpharma.com, in the "Investors"
section. Management will refer to a slide presentation during
the call, which will be made available on the day of the call. To
view the presentation, select "Presentations" in the "Investors"
section of the Company's website.
An online archive of the broadcast will be available at the
website three hours after the live call and will be available
through Thursday, May 6, 2021, by
dialing 855-859-2056 (U.S.) or 404-537-3406 (International) and
entering conference ID 4285757.
Forward-Looking Statements
Certain forward-looking
statements appear in this release and include such words as
"raising," "believe," "continue," "remain," "foreseeable,"
"expected," "to be," "includes," "estimated," "assumes,"
"potential," "would provide," and other similar terminology.
These statements reflect management's current expectations
regarding future events and operating performance and speak only as
of the date of this release. There is no certainty that
actual results will be achieved in-line with current
expectations. These forward-looking statements involve a
number of risks and uncertainties. The following are some of
the factors that could cause our actual results to differ
materially from those expressed in or underlying our
forward-looking statements: the duration and severity of the global
COVID-19 pandemic, including prevailing economic conditions and
general uncertainties relating thereto that may be unknown and
unforeseeable; customers' changing inventory requirements and
manufacturing plans and customer decisions to move forward with our
new products and product categories, including any
re-prioritization of product needs due to COVID-19; other potential
impacts from COVID-19, including interruptions or weaknesses in our
supply chain, illness in our workforce and access to transport for
our products; average profitability, or mix, of the products we
sell; dependence on third-party suppliers and partners; increased
raw material costs; fluctuations in currency exchange; and the
ability to meet development milestones with key customers.
This list of important factors is not all inclusive. For a
description of certain additional factors that could cause the
Company's future results to differ from those expressed in any such
forward-looking statements, see Part I Item 1A , entitled "Risk
Factors," in the Company's Annual Report on Form 10-K for the year
ended December 31, 2020.
Except as required by law or regulation, we undertake no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Non-U.S. GAAP Financial Measures
For the purpose of
aiding the comparison of our year-over-year results, we may refer
to net sales and other financial results excluding the effects of
changes in foreign currency exchange rates. Organic net sales
exclude the impact from acquisitions and/or divestitures and
translate the current-period reported sales of subsidiaries whose
functional currency is other than the U.S. Dollar at the applicable
foreign exchange rates in effect during the comparable prior-year
period. We may also refer to financial results excluding the
effects of unallocated items. The re-measured results
excluding effects from currency translation and excluding the
effects of unallocated items are not in conformity with U.S.
generally accepted accounting principles ("U.S. GAAP") and should
not be used as a substitute for the comparable U.S. GAAP financial
measures. The non-U.S. GAAP financial measures are
incorporated into our discussion and analysis as management uses
them in evaluating our results of operations and believes that this
information provides users a valuable insight into our overall
performance and financial position. A reconciliation of these
adjusted Non-U.S. GAAP measures to the comparable U.S. GAAP
financial measures is included in the accompanying tables.
WEST
PHARMACEUTICAL SERVICES, INC.
|
CONSOLIDATED
STATEMENTS OF INCOME
|
(UNAUDITED)
|
(in millions,
except per share data)
|
|
|
|
Three Months
Ended March
31,
|
|
2021
|
2020
|
Net sales
|
$670.7
|
100%
|
491.5
|
100%
|
Cost of goods and
services sold
|
398.8
|
59
|
324.5
|
66
|
Gross
profit
|
271.9
|
41
|
167.0
|
34
|
Research and
development
|
12.2
|
2
|
10.7
|
2
|
Selling, general and
administrative expenses
|
80.2
|
12
|
71.8
|
14
|
Other expense
(income)
|
3.9
|
1
|
(3.5)
|
-
|
Operating
profit
|
175.6
|
26
|
88.0
|
18
|
Interest expense,
net
|
1.8
|
-
|
1.2
|
-
|
Other nonoperating
(income) expense
|
(1.1)
|
-
|
0.3
|
-
|
Income before income
taxes
|
174.9
|
26
|
86.5
|
18
|
Income tax
expense
|
28.7
|
4
|
15.0
|
3
|
Equity in net income
of affiliated companies
|
(5.0)
|
(1)
|
(2.8)
|
-
|
Net income
|
$151.2
|
23%
|
$74.3
|
15%
|
|
|
|
|
|
Net income per
share:
|
|
|
|
|
Basic
|
$2.04
|
|
$1.01
|
|
Diluted
|
$1.99
|
|
$0.99
|
|
|
|
|
|
|
Average common shares
outstanding
|
73.9
|
|
73.9
|
|
Average shares
assuming dilution
|
75.8
|
|
75.5
|
|
WEST
PHARMACEUTICAL SERVICES
|
REPORTING SEGMENT
INFORMATION
|
(UNAUDITED)
|
(in
millions)
|
|
|
Three Months
Ended
|
|
March
31,
|
Net
Sales:
|
2021
|
2020
|
Proprietary
Products
|
$543.7
|
$373.5
|
Contract-Manufactured
Products
|
127.1
|
118.1
|
Eliminations
|
(0.1)
|
(0.1)
|
Consolidated
Total
|
$670.7
|
$491.5
|
|
|
|
Gross
Profit:
|
|
|
Proprietary
Products
|
$251.9
|
$150.1
|
Contract-Manufactured
Products
|
20.0
|
16.9
|
Gross
Profit
|
$271.9
|
$167.0
|
Gross Profit
Margin
|
40.5%
|
34.0%
|
|
|
|
Operating Profit
(Loss):
|
|
|
Proprietary
Products
|
$182.6
|
$93.2
|
Contract-Manufactured
Products
|
16.4
|
12.8
|
Stock-based
compensation expense
|
(5.9)
|
(5.4)
|
General corporate
costs
|
(13.9)
|
(12.6)
|
Adjusted Operating
Profit
|
$179.2
|
$88.0
|
Adjusted Operating
Profit Margin
|
26.7%
|
17.9%
|
Other unallocated
items
|
(3.6)
|
-
|
Reported Operating
Profit
|
$175.6
|
$88.0
|
Reported Operating
Profit Margin
|
26.2%
|
17.9%
|
WEST
PHARMACEUTICAL SERVICES
|
RECONCILIATION OF
NON-GAAP MEASURES (UNAUDITED)
|
Please refer to
"Non-U.S. GAAP Financial Measures" for more
information
|
(in millions,
except per share data)
|
|
Reconciliation of
Reported and Adjusted Operating Profit, Net Income and Diluted
EPS
|
|
Three months ended
March 31, 2021
|
Operating
profit
|
Income
tax
expense
|
Net
income
|
Diluted
EPS
|
Reported (U.S.
GAAP)
|
$175.6
|
$28.7
|
$151.2
|
$1.99
|
Unallocated
items:
|
|
|
|
|
Restructuring and
related charges (1)
|
1.2
|
0.2
|
1.0
|
0.01
|
Pension Settlement
(2)
|
-
|
0.2
|
0.5
|
0.01
|
Amortization of
Acquisition-related Intangible Assets (3)
|
0.2
|
-
|
0.7
|
0.01
|
Cost investment
impairment
|
2.2
|
-
|
2.2
|
0.03
|
Adjusted (Non-U.S.
GAAP)
|
$179.2
|
$29.1
|
$155.6
|
$2.05
|
|
Three months ended
March 31, 2020
|
Operating
profit
|
Income
tax
expense
|
Net
income
|
Diluted
EPS
|
Reported (U.S.
GAAP)
|
$88.0
|
$15.0
|
$74.3
|
$0.99
|
Pension Settlement
(2)
|
-
|
0.3
|
1.1
|
0.01
|
Amortization of
Acquisition-related Intangible Assets (3)
|
-
|
-
|
1.0
|
0.01
|
Adjusted (Non-U.S.
GAAP)
|
$88.0
|
$15.3
|
$76.4
|
$1.01
|
|
|
(1)
|
During the three
months ended March 31, 2021, the Company recorded $1.2 million in
restructuring and related charges in connection with its 2020 plan
to optimize certain organizational structures within the
Company.
|
|
|
(2)
|
During the three
months ended March 31, 2021 and March 31, 2020, the Company
recorded a pension settlement charge of $0.6 million and $1.4
million, respectively, within other nonoperating (income) expense,
as it determined that normal-course lump-sum payments for our U.S.
qualified defined benefit pension plan exceeded the threshold for
settlement accounting.
|
|
|
(3)
|
During the three
months ended March 31, 2021, the Company recorded $0.2 million of
amortization expense within operating profit associated with an
acquisition of an intangible asset during the second quarter of
2020. During the three months ended March 31, 2021 and 2020 the
Company recorded $0.5 million and $1.0 million of amortization
expense, respectively, in association with an acquisition of
increased ownership interest in Daikyo.
|
WEST
PHARMACEUTICAL SERVICES
|
RECONCILIATION OF
NON-GAAP MEASURES (UNAUDITED)
|
Please refer to
"Non-U.S. GAAP Financial Measures" for more
information
|
(in millions,
except per share data)
|
|
Reconciliation of
Net Sales to Organic Net Sales (4)
|
|
Three months ended
March 31, 2021
|
Proprietary
|
CM
|
Eliminations
|
Total
|
Reported net sales
(U.S. GAAP)
|
$543.7
|
$127.1
|
$(0.1)
|
$670.7
|
Effect of changes in
currency translation rates
|
22.2
|
4.3
|
-
|
26.5
|
Organic net sales
(Non-U.S. GAAP) (4)
|
$565.9
|
$131.4
|
$(0.1)
|
$697.2
|
|
|
(4)
|
Organic net sales
exclude the impact from acquisitions and/or divestitures and
translate the current-period reported sales of subsidiaries whose
functional currency is other than the U.S. dollar at the applicable
foreign exchange rates in effect during the comparable prior-year
period.
|
WEST
PHARMACEUTICAL SERVICES
|
RECONCILIATION OF
NON-GAAP MEASURES (UNAUDITED)
|
Please refer to
"Non-U.S. GAAP Financial Measures" for more
information
|
(in millions,
except per share data)
|
|
Reconciliation of
Reported-Diluted EPS Guidance to Adjusted-Diluted EPS
Guidance
|
|
|
2020
Actual
|
2021
Guidance
|
% Change
|
Reported-diluted EPS
(U.S. GAAP)
|
$4.57
|
$6.86 to
$7.01
|
50.1% to
53.4%
|
Restructuring and
related charges
|
0.07
|
0.01
|
-
|
Pension
settlement
|
0.04
|
0.01
|
-
|
Amortization of
acquisition-related intangible assets
|
0.05
|
0.04
|
-
|
Cost investment
impairment
|
0.03
|
0.03
|
-
|
Adjusted-diluted EPS
(Non-U.S. GAAP) (5)
|
$4.76
|
$6.95 to
$7.10
|
46.0% to
49.2%
|
|
|
|
Notes:
|
|
|
|
|
See "Full-year 2021
Financial Guidance" and "Non-U.S. GAAP Financial Measures" in
today's press release for additional information regarding
adjusted-diluted EPS.
|
|
|
|
|
(5)
|
We have opted not to
forecast 2021 tax benefits from stock-based compensation in
upcoming quarters, as they are out of the Company's control.
Instead, we recognize the benefits as they occur. In the
first-quarter 2021, tax benefits associated with stock-based
compensation increased adjusted-diluted EPS by $0.15. Any
future tax benefits associated with stock-based compensation that
we receive in 2021 would provide a positive adjustment to our
full-year EPS guidance. In 2020, tax benefits associated with
stock-based compensation increased adjusted-diluted EPS by
$0.27.
|
WEST
PHARMACEUTICAL SERVICES
|
CASH FLOW
ITEMS
|
(UNAUDITED)
|
(in
millions)
|
|
|
Three Months Ended
March 31,
|
|
2021
|
2020
|
Depreciation and
amortization
|
$29.1
|
$26.0
|
Operating cash
flow
|
$88.7
|
$57.1
|
Capital
expenditures
|
$54.7
|
$32.1
|
WEST
PHARMACEUTICAL SERVICES
|
FINANCIAL
CONDITION
|
(UNAUDITED)
|
(in
millions)
|
|
|
As
of March 31, 2021
|
As
of December 31, 2020
|
Cash and cash
equivalents
|
$483.7
|
$615.5
|
Accounts receivable,
net
|
$465.7
|
$385.3
|
Inventories
|
$310.2
|
$321.3
|
Accounts
payable
|
$204.3
|
$213.1
|
Debt
|
$254.6
|
$255.2
|
Equity
|
$1,829.0
|
$1,854.5
|
Working
capital
|
$844.2
|
$870.3
|
Trademark Notices
Trademarks and registered trademarks are the property of West
Pharmaceutical Services, Inc., in the
United States and other jurisdictions, unless noted
otherwise.
Daikyo®, Daikyo Crystal
Zenith® and Daikyo CZ® are registered
trademarks of Daikyo Seiko, Ltd. Daikyo Crystal Zenith
technologies are licensed from Daikyo Seiko, Ltd.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/west-announces-first-quarter-2021-results-301279684.html
SOURCE West Pharmaceutical Services, Inc.